0001104659-24-049988.txt : 20240422 0001104659-24-049988.hdr.sgml : 20240422 20240422161000 ACCESSION NUMBER: 0001104659-24-049988 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240420 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240422 DATE AS OF CHANGE: 20240422 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ArriVent Biopharma, Inc. CENTRAL INDEX KEY: 0001868279 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41929 FILM NUMBER: 24861289 BUSINESS ADDRESS: STREET 1: 18 CAMPUS BLVD. STREET 2: SUITE 100 CITY: NEWTOWN SQUARE STATE: PA ZIP: 19073-3269 BUSINESS PHONE: 240-780-6356 MAIL ADDRESS: STREET 1: 18 CAMPUS BLVD. STREET 2: SUITE 100 CITY: NEWTOWN SQUARE STATE: PA ZIP: 19073-3269 8-K 1 tm2412347d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 20, 2024

ARRIVENT BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41929		86-3336099
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

18 Campus Boulevard, Suite 100

Newtown Square, PA

19073

(Address of principal executive offices)

(zip code)

Registrant’s telephone number, including area code: (628) 277-4836

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		AVBP		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02               Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 20, 2024, the Board of Directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) appointed Kristine Peterson to the Board, effective immediately (the “Effective Date”). Ms. Peterson will serve as a Class III Director until the Company’s 2027 annual meeting of stockholders and until her successor has been duly elected and qualified, or until her earlier death, resignation, retirement or removal.

Ms. Peterson, age 64, most recently served as Chief Executive Officer for Valeritas, Inc. from 2009 to 2016. Prior to joining Valeritas, Ms. Peterson was Company Group Chair of the biotechnology group at Johnson & Johnson from 2006 until 2009, where she was responsible for Commercial, Research & Development, and biologics manufacturing for oncology, immunology and cell therapy, and was Executive Vice President of Pharmaceutical Group Strategic Marketing from 2004 to 2006. Previously, she served as President and Senior Vice President, Commercial Operations for Biovail Corporation. Earlier in her career, Ms. Peterson spent 20 years at Bristol-Myers Squibb Company in a variety of senior roles across multiple disease areas, including running their cardiovascular and metabolics business unit. Ms. Peterson has served on the boards of directors of Enanta Pharmaceuticals since September 2017 and Immunocore Holdings since November 2017. She previously served on the boards of directors for ImmunoGen, Inc., Amarin Corporation plc, EyePoint Pharmaceuticals and Paratek Pharmaceuticals. Additionally, she previously served as a senior advisor to the Healthcare Businesswomen’s Association and a Member of the Biotechnology Industry Organization (BIO) Board. Ms. Peterson has a B.S. and an M.B.A. from the University of Illinois at Urbana-Champaign.

The Board has affirmatively determined that Ms. Peterson is an independent director pursuant to the Nasdaq Stock Market’s governance listing standards and those rules and regulations issued pursuant to the Securities Exchange Act of 1934, as amended. There are no arrangements or understandings between Ms. Peterson and any other person pursuant to which Ms. Peterson was appointed as a director. There are no transactions to which the Company is a party and in which Ms. Peterson has a material interest that are required to be disclosed under Item 404(a) of Regulation S-K. Ms. Peterson has not previously held any positions with the Company and has no family relations with any directors or executive officers of the Company. Currently, the Board has not made a determination regarding any committee assignments for Ms. Peterson.

Ms. Peterson will be entitled to the standard compensation paid by the Company to its non-employee directors under the Company’s Non-Employee Director Compensation Policy (the “Non-Employee Director Compensation Policy”), a copy of which is filed as Exhibit 10.5 of the Company’s Registration Statement on Form S-1, as amended (File No. 333-276397), filed with the Securities and Exchange Commission on January 5, 2024 (the “Form S-1”). Pursuant to the Non-Employee Director Compensation Policy, on the Effective Date, Ms. Peterson was granted a non-qualified stock option to purchase shares of the Company’s common stock, effective as of April 22, 2024 (the “Grant Date”), with a Grant Date fair value of $235,000 (the “Option”). The Option will vest one year following the Grant Date, subject to Ms. Peterson continuing to provide services to the Company through such vesting. In addition, Ms. Peterson is entitled to receive an annual cash retainer of $45,000 for her service as a non-employee director of the Company pursuant to the Company’s Non-Employee Director Compensation Policy, prorated for the portion of the year that Ms. Peterson serves as a director.

Ms. Peterson will also enter into an indemnification agreement in the form the Company has entered into with its other non-employee directors, which form is filed as Exhibit 10.1 to the Form S-1.

A copy of the press release announcing Ms. Peterson’s appointment to the Board is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01            Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated April 22, 2024.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ARRIVENT BIOPHARMA, INC.

	By:	/s/ Winston Kung, MBA
		Winston Kung, MBA
		Chief Financial Officer and Treasurer

Date: April 22, 2024

EX-99.1 2 tm2412347d1_exx99-1.htm EXHIBIT 99.1

Exhibit 99.1

ArriVent Appoints Kristine Peterson to its Board of Directors

NEWTON SQUARE, PA – April 22, 2024 – ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Kristine Peterson to its Board of Directors. Ms. Peterson brings over 30 years of biopharmaceutical leadership experience, and currently serves on the Boards of public companies Immunocore, Inc. and Enanta Pharmaceuticals.

“We are thrilled for Kris to join our Board of Directors at such an important time for ArriVent, as we advance the development of firmonertinib in multiple non-small cell lung cancer (“NSCLC”) indications,” said Bing Yao, Chairman and Chief Executive Officer of ArriVent. “Kris has a proven track record of strong leadership across the biotech and pharmaceutical industries, with experience successfully launching and commercializing multiple products. Her insight and counsel as a member of our Board will be invaluable as we work to maximize the potential of our pipeline and ensure our medicines reach the patients who need them most.”

“I am excited to work alongside ArriVent’s talented management team and Board of Directors to help address the unmet needs of cancer patients,” said Ms. Peterson. “I look forward to providing strategic insights to support ArriVent’s mission of identifying and developing potentially transformative medicines.”

Ms. Peterson has served as a Board Member for multiple companies, including ImmunoGen, Inc., Immunocore, Inc., Enanta Pharmaceuticals, Paratek Pharmaceuticals, Amarin Corporation and EyePoint Pharma. Most recently, she served as Chief Executive Officer for Valeritas, Inc., where she led the company’s development from early-stage R&D through to commercialization. Prior to Valeritas, Ms. Peterson held executive leadership roles at Johnson & Johnson, including Company Group Chair for their worldwide biotech and oncology groups, where she grew those businesses to more than $6 billion in sales, launched several new products, licensed new therapeutics, and rebuilt oncology R&D. Previously, she was also President and Senior Vice President, Commercial Operations for Biovail Corporation, where she oversaw the U.S. and Canadian business units. Earlier in her career, Ms. Peterson spent 20 years at Bristol-Myers Squibb in a variety of senior roles, including running their cardiovascular and metabolics business unit. She earned her B.S. and M.B.A from the University of Illinois at Urbana-Champaign.

About ArriVent

ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding ArriVent’s ability to develop drugs that help to address the unmet needs of cancer patients, the timing, progress and results of pre-clinical studies and clinical trials for firmonertinib, including our product development plans and strategies, ArriVent’s clinical programs future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on ArriVent’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in ArriVent’s annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on March 28, 2024, and its other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and ArriVent undertakes no duty to update such information except as required under applicable law.

Contact for Investors & Media:

Argot Partners

212.600.1902

ArriVent@argotpartners.com

1

EX-101.SCH 3 avbp-20240420.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 avbp-20240420_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 avbp-20240420_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2412347d1_ex99-1img001.jpg GRAPHIC begin 644 tm2412347d1_ex99-1img001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^FE@*5NE M<_XQU)],\,WO?UKO=/U>2:RB9S\X&UN>XKU9Y>H MI-,\I9@V]#U"'4[:=MJMAB< ''-6PP->7+J;*P8-@@Y'->BZ9>+J&GPW*X^= MA[C\ZX:]!T[/H=F'Q"JW3W+F:,TGXT?C7,=8N:,UEW7B'1K&\^QW>JV4% MSQ^ZEG57YZ<$YYK3% "YHS6;?:_I&F3+#?ZG9VLK+N"3S*A(]<$U6'B_PVS M#7],)/ ND_QH V\T9IB.LB!D8,I&01R#6=>>(M%TZY:VO=6LK:=0"8YIU5@ M#TX)H U,T9K$7Q=X;9@JZ_IA). !=)S^M;*LKJ&5@RGD$=Z '9HS5%M7T]-2 M733?6XOF&5MC(/,(QG[N<] 339M;TNWU!-/FU&UCO7P$MVE4.V>F%SGF@#0S M1FD[51GUG3;;4(K">_MH[R7'EP/* [YR!A>IZ&@"_FC-9M]KVDZ7,L.H:G9V MLC+N5)YE0D>N":K?\)AX:_Z/_ *3_&@#;S2U0L-6T_54=]/OK:[6,@.T M$@<*>O.#3K75+&]FF@M;R":6!MDR1R!C&>>& Z'@T 7,T9ICLJ*79@%49)/ M JG8:OIVJ122V%_;74<9P[PR!PIQG!(Z<4 7\T9K#_X3#PUWU_3/_ I/\:/^ M$Q\,C_F8-,_\"D_QH W:*C@FBN;>.>"19(I4#HZ'(92,@@^F** 'MTKBO&VD MZQK,]O!9VQDM8P7)WJ,N>.Y[#^==A=W,-G:R7%Q((X8P6=CT %>;2_%J/[84 MATQO(W8$CRN *ZL-"HY\U-7L!SZYQ^=;Z>.)I4#I:1,I&00QJ9?$=OJT,EA?0")) MT*;]V0">GTKT)5<4K.459'DJGA-5&3OYG ^<:[;P#J19+>"2:5@L<:EV8]@!DFEBD65$=2"K $$=Q7!?%W7AI7A%K**;;(?!VGWTSAK@H8YCC&74[2?QQG\:\K\-^+-3\/>&%T-?"-W/"P?SG>.3,A< MG)/R^^/H*O\ P9U2XL=:U'P_=+)")4^T10RJ596& 1SSRI4_\!H B^*5E%J/ MQ2T.QF+"*YB@A7^HW'V4?+(89@2H/@#;^% M>J7NG^*=7\(SSFXMK4R-$Y)^4QN$./0'.<=B/>J/BC1+7Q'\;H]*O'D2"XA& MYHB PVPEA@D'N!VKH_A!HNGVN@R:Q%=K=7][Q.W>$ D[/7.3DGOP:Y3QK#J] MQ\8_*T&7R]2:%/);=MQ^Z);G_=S0!U$GP3\.E&"7VI*V, F2,@?ALK/^$NI7 MEAXBUCPG/+Y]O:F1XI,_=*.$('H#D''L:PM7^I3_95&)&BGR5! MXSP 0/>NN^#>CV5MX>EU:*Y6YO;Q]LQ P8@O1.>>^2>^13 S[\?\9#V'_7'_ M -H/4WQ@TF2U.F>*K)#]ILI421AZ!MR$_1N/^!5%?_\ )P]A_P!,_B5JWBF=6,-I_Q[*W8ME4X]D!X]6S7,Z3XNFT7X=:[X?NC(EWYWDP M1MU17W>8/PVM^+UZS\,]!&A>"K19(C'=78^TW ;J&;H#]%"C\* .)^*%C!J? MQ-\/V-T[+;W$,4JAI6!(S6I_P *4T/_ *#%]_WTG_Q- '9>$_"6F>$[2>+2 MY9Y(KEQ(S2NKE M>X^+=$NM>TJ*UM'A21)Q(3*2!@*P[ \\BN+/PXUK'%QI^?>1_P#XBO9P5>E3 MI6D[.YX>.I5YU;PBVK&;X.TB\U#[6D1 MX5#<]W/8?AG]*U7LVCU9?4\ BLI8V]1]BE@'[)/[1 MY-K4#07*RG.V0=3ZC_ZV*S?,'K7>Z]X*UO4Y(TMIM/2"/)&^1PQ)^BFL?_A6 M?B#_ )^=-_[^R?\ Q%=D,72Y5>1@\%4['9^"M474= BCS^]M?W+?0?=_3'Y5 MG^)O /\ PD_BG3]4NK[;:V80?9@GWL,6//OP/H*T_"'AN;P]I\B7,L)6<7-N.Q[E%24$I;C=H]!^5<=JO@9[OQS9>)[*_\ LLT( M42Q[,B0#(/YJ?4 M9QFK4G@HR?$6'Q7]L \M-OD;.O[LIU_'-=?BC% $,\$=S;R03(LD4BE71AD, M#U!KC?"?@*X\):U=3VFJ%].N"Q-HR=.?EY]1TS7<8HQ0!R$_@HS?$2W\5?; M!$FWR-G7Y&7K^-=<>12XHQ0!YOK/PGMM6\7OK7VW9!+.DTMOLSNQC<,_[6#^ M=>CCBEQ1B@#@O&WP[?Q=J]M?IJ7V4PP"+;LSG#$YS^-$+.[@>_:[-Q('W$$;<#&*9X=\%'0O%>L:V;P3?VBSMY>S M&S<^_KWKK\48H SM:T:SU[2YM/OHP\,HP?53V(]"*P_ G@S_ (0NQO;;[9]I M%S.)=VW;MPH7'Z5UN*,4 4M5LCJ6D7MB'V?:8)(=V,[=RD9_6LCP5X7/A'0V MTXW(N-TS2[PNWJ ,?I728HQ0 O:BBB@ HHHH **** "BBB@ HHHH **** "B IBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D! end XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	Apr. 20, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Apr. 20, 2024
Entity File Number	001-41929
Entity Registrant Name	ARRIVENT BIOPHARMA, INC.
Entity Central Index Key	0001868279
Entity Tax Identification Number	86-3336099
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	18 Campus Boulevard
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Newtown Square
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19073
City Area Code	628
Local Phone Number	277-4836
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	AVBP
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://arrivent.com/role/Cover Cover Cover 1 false false All Reports Book All Reports avbp-20240420.xsd avbp-20240420_lab.xml avbp-20240420_pre.xml tm2412347d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2412347d1_8k.htm": { "nsprefix": "avbp", "nsuri": "http://arrivent.com/20240420", "dts": { "schema": { "local": [ "avbp-20240420.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "avbp-20240420_lab.xml" ] }, "presentationLink": { "local": [ "avbp-20240420_pre.xml" ] }, "inline": { "local": [ "tm2412347d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://arrivent.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-04-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2412347d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2412347d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-049988-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-049988-xbrl.zip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end XML 18 tm2412347d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001868279 2024-04-20 2024-04-20 iso4217:USD shares iso4217:USD shares false 0001868279 8-K 2024-04-20 ARRIVENT BIOPHARMA, INC. DE 001-41929 86-3336099 18 Campus Boulevard Suite 100 Newtown Square PA 19073 628 277-4836 false false false false Common Stock, $0.0001 par value per share AVBP NASDAQ true false